Literature DB >> 10510285

NADPH-dependent microsomal electron transfer increases degradation of CYP2E1 by the proteasome complex: role of reactive oxygen species.

T Goasduff1, A I Cederbaum.   

Abstract

Increased levels of cytochrome P450 2E1 (CYP2E1) produced by low-molecular-weight compounds is mostly due to stabilization of the enzyme against proteolytic degradation. CYP2E1, in the absence of substrate or ligand, normally has a short half-life, but the factors which regulate CYP2E1 turnover or trigger its rapid degradation are not known. Since CYP2E1 is active in producing reactive oxygen species, experiments were carried out to evaluate whether reactive oxygen species modulated the degradation of CYP2E1. CYP2E1 present in human liver microsomes was very stable. Addition of the cytosol fraction produced degradation of CYP2E1, and this was enhanced when NADPH was present in the reaction system. Antioxidants or iron chelators which prevent lipid peroxidation, prevented the degradation of CYP2E1 by the cytosolic fraction. Similarly, diphenyleneiodonium chloride, which inhibits NADPH-dependent electron transfer, prevented the degradation of CYP2E1, as did 4-methylpyrazole, a ligand which increases the level of CYP2E1. If microsomes were first incubated with NADPH for 30 min, followed by the addition of these agents, there was no protection against CYP2E1 degradation. Lactacystin, an inhibitor of the proteasome, decreased the degradation of CYP2E1. In intact HepG2 cells transduced to express CYP2E1, proteasome inhibitors elevated steady-state levels of CYP2E1. Steady-state levels of CYP2E1 were increased by about 50% when the cells were incubated with trolox. Trolox decreased the rate of loss of CYP2E1 protein when the cells were treated with cycloheximide. These results suggest that NADPH-dependent production of reactive oxygen species may result in oxidative modification of CYP2E1, followed by rapid degradation of the labilized CYP2E1 by the proteasome complex. It is interesting to speculate that one consequence of the high rates of production of reactive oxygen species by CYP2E1 is its own labilization and subsequent rapid degradation, and this may be a regulatory mechanism to prevent high levels of the enzyme from accumulating within the cell. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510285     DOI: 10.1006/abbi.1999.1399

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  14 in total

1.  Impaired methylation as a novel mechanism for proteasome suppression in liver cells.

Authors:  Natalia A Osna; Ronda L White; Terrence M Donohue; Michael R Beard; Dean J Tuma; Kusum K Kharbanda
Journal:  Biochem Biophys Res Commun       Date:  2009-12-21       Impact factor: 3.575

2.  Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination.

Authors:  YongQiang Wang; Shenheng Guan; Poulomi Acharya; Dennis R Koop; Yi Liu; Mingxiang Liao; Alma L Burlingame; Maria Almira Correia
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 3.  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Authors:  Sung-Mi Kim; YongQiang Wang; Noushin Nabavi; Yi Liu; Maria Almira Correia
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

4.  Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance.

Authors:  Sung-Mi Kim; Poulomi Acharya; Juan C Engel; Maria Almira Correia
Journal:  J Biol Chem       Date:  2010-09-06       Impact factor: 5.157

Review 5.  Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal.

Authors:  Maria Almira Correia; Peter R Sinclair; Francesco De Matteis
Journal:  Drug Metab Rev       Date:  2010-09-23       Impact factor: 4.518

6.  An in vitro comparative study with furyl-1,4-quinones endowed with anticancer activities.

Authors:  Julio Benites; Jaime A Valderrama; Henryk Taper; Pedro Buc Calderon
Journal:  Invest New Drugs       Date:  2010-03-17       Impact factor: 3.850

Review 7.  Hepatic cytochrome P450 ubiquitination: conformational phosphodegrons for E2/E3 recognition?

Authors:  Maria Almira Correia; YongQiang Wang; Sung-Mi Kim; Shenheng Guan
Journal:  IUBMB Life       Date:  2014-02-03       Impact factor: 3.885

8.  A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation.

Authors:  Yongqiang Wang; Mingxiang Liao; Nicholas Hoe; Poulomi Acharya; Changhui Deng; Andrew N Krutchinsky; Maria Almira Correia
Journal:  J Biol Chem       Date:  2008-12-18       Impact factor: 5.157

9.  Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.

Authors:  Wataru Okiyama; Naoki Tanaka; Tamie Nakajima; Eiji Tanaka; Kendo Kiyosawa; Frank J Gonzalez; Toshifumi Aoyama
Journal:  J Hepatol       Date:  2009-04-02       Impact factor: 25.083

10.  Sarcolipin and ubiquitin carboxy-terminal hydrolase 1 mRNAs are over-expressed in skeletal muscles of alpha-tocopherol deficient mice.

Authors:  Vihas T Vasu; Sean Ott; Brad Hobson; Vania Rashidi; Saji Oommen; Carroll E Cross; Kishorchandra Gohil
Journal:  Free Radic Res       Date:  2009-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.